
- Oncology NEWS International Vol 15 No 12
- Volume 15
- Issue 12
Pharmion Purchases Cabrellis, US Developer of Amrubicin
Pharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II trials for small-cell lung cancer in North America and Europe.
BOULDER, ColoradoPharmion Corporation has acquired Cabrellis Pharmaceuticals and gained US and European rights to amrubicin, a third-generation synthetic anthracycline currently in phase II trials for small-cell lung cancer in North America and Europe.
Articles in this issue
almost 19 years ago
Best Rx Most Cost-Effective: RTOGalmost 19 years ago
Grape Seed Found to Be a Natural Aromatase Inhibitoralmost 19 years ago
Drug Combination Prevents ER-Negative Tumors in Micealmost 19 years ago
Democrats' Agenda May Stifle Efforts for More Ca Fundingalmost 19 years ago
No Loss of Efficacy With Synchronous Chemotherapy/ESPalmost 19 years ago
'Share Care' Difficult for Ca Survivors and Their Oncologistsalmost 19 years ago
Biomarkers Panel Promising for Detecting Pancreatic Caalmost 19 years ago
Preop Avastin/Tarceva in RCCalmost 19 years ago
Reovirus Agent Shows Activity in Phase I TrialNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.